Latest news with #Zimmer
Express Tribune
44 minutes ago
- Entertainment
- Express Tribune
Hans Zimmer joins ‘Euphoria' season 3 as composer alongside Labrinth
Oscar-winning composer Hans Zimmer has officially joined the creative team of Euphoria Season 3, marking a major musical shift for the hit HBO drama. Zimmer will work alongside returning composer Labrinth, whose sound has defined the show's haunting and emotional tone in its first two seasons. The news was announced on social media Wednesday, with Zimmer expressing excitement about the collaboration. 'It's an honor to join this incredible team of storytellers led by the visionary Sam Levinson,' he said. 'Labrinth's music has shaped the show's identity, and I look forward to helping shape this new season through music.' Labrinth, who composed standout tracks like 'All for Us' and 'I'm Tired,' also welcomed the opportunity to collaborate. 'So great to join Hans, one of my heroes in film score, and bring some new magic to this new season,' he said. Zimmer's involvement adds prestige and anticipation, as the acclaimed composer is known for iconic film scores in Interstellar, The Lion King, Gladiator, Inception, and Dune. His cinematic influence has already been part of the show's DNA, according to creator Sam Levinson, who revealed that he wrote parts of the season while listening to Zimmer's scores from Interstellar and True Romance. 'Euphoria' Season 3 has yet to receive a release date, but the addition of Zimmer signals a bold creative evolution for the series. With both Zimmer and Labrinth shaping the sonic landscape, fans can expect a fresh yet emotionally grounded score that elevates the storytelling to new heights.
Malaysian Reserve
5 days ago
- Business
- Malaysian Reserve
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: MGRM, EPIX, BLBX, and PBBK
NEW YORK, July 18, 2025 /PRNewswire/ — Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the 'M&A Class Action Firm'), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Monogram Technologies Inc. (NASDAQ: MGRM) related to its sale to Zimmer Biomet Holdings, Inc. Under the terms of the proposed transaction, Monogram shareholders would receive an upfront payment of $4.04 per share in cash, and one non-tradeable contingent value right collectively worth up to $12.37 per share in cash payable (i) $1.04 upon completion of a proof-of-concept demonstration of Monogram's robotic system for unicompartmental (partial) knee arthroplasty made available to Zimmer's designated executives on or before the later January 31, 2026 or 30 days following the Closing; (ii) $1.08 upon the grant of 510(k) clearance by the FDA for Monogram's fully autonomous robotic system for use with Zimmer implants, as evidenced by formal clearance indicating substantial equivalence to a predicate device, on or before December 31, 2027; (iii) $3.41 when the company achieves gross revenue of at least $156 million between January 1, 2028 and December 31, 2028; (iv) $3.41 when the company achieves gross revenue of at least $381 million between January 1, 2029 and December 31, 2028; and (v) $3.43 when the company achieves gross revenue of at least $609 million between January 1, 2030 and December 31, 2030. Click here for more information It is free and there is no cost or obligation to you. ESSA Pharma Inc. (NASDAQ: EPIX) related to its sale to Xeno Acquisition Corp. Upon completion of the transaction, ESSA shareholders will receive a cash payment per share to be calculated based upon ESSA's cash balance at closing minus transaction costs, liability and legal exposure review, and a $4 million transaction fee payable to Xeno. Additionally, ESSA shareholders are entitled to receive one non-transferable contingent value right per share entitling them to future payments based on (i) up to $150,000.00, less any remaining liabilities and expenses not deducted at closing; and (ii) up to $2.8 million, less legal and other expenses incurred after closing. Click here for more information It is free and there is no cost or obligation to you. Blackboxstocks Inc. (NASDAQ: BLBX), relating to the proposed merger with REalloys Inc. Under the terms of the agreement, it is anticipated Blackbox's stockholders will own approximately 7.3% of the combined company's common stock. Click here for more information It is free and there is no cost or obligation to you. PB Bankshares Inc. (NASDAQ: PBBK) related to its sale to Norwood Financial Corp. Under the terms of the proposed transaction, PB Bankshares' shareholders will have the option to elect to receive either 0.7850 shares of Norwood common stock or $19.75 in cash for each common share of PB Bankshares they own. The election is subject to proration to ensure that, in the aggregate, 80% of the transaction consideration will be paid in the form of Norwood common stock. Click here for more information It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask: Do you file class actions and go to Court? When was the last time you recovered money for shareholders? What cases did you recover money in and how much? About Monteverde & Associates PC Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. No company, director or officer is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@ or by telephone at (212) 971-1341. Contact:Juan Monteverde, & ASSOCIATES PCThe Empire State Building350 Fifth Ave. Suite 4740New York, NY 10118United States of Americajmonteverde@ (212) 971-1341 Attorney Advertising. (C) 2025 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC ( Prior results do not guarantee a similar outcome with respect to any future matter.
India Today
6 days ago
- Entertainment
- India Today
Namita Malhotra says Hans Zimmer called Ramayana beyond time and human imagination
'Ramayana' producer Namit Malhotra recently shared his interaction with Oscar-winning composer Hans Zimmer. He recalled Zimmer's understanding of the ancient epic and how passionately he felt about a podcast with Prakhar Gupta, Malhotra recounted a conversation with Zimmer. He stated that the composer stopped him mid-discussion related to 'Ramayana'.The producer, while quoting Zimmer, said, "It's clearly something beyond us. You and I don't need to explain it."advertisement He further quoted the 'The Lion King' composer and said, "You don't have to explain it (Ramayana) to me. Something that has lived through thousands of years, generations of people, and continues to be relevant after all of that time you and I don't need to explain it. Something is there, why it is relevant even today. Let's acknowledge it and let's do the best we can because it's clearly something that's beyond us."Malhotra is also the founder and non-executive director of Prime Focus Limited, the parent company of the visual effects studio DNEG. In addition to that, he serves as the chairperson and CEO of speaking about 'Ramayana' in the same podcast, Malhotra emphasised on the need to change the Western perception about India. He said, "I was like, 'no, that's not who we are'. That's not where my core strength and energy come from. Ramayana became that story for me. How do I take this and present something that is the evolution of the planet, that's the first civilisation in the world? That's the greatest in the world."The upcoming two-part film series is based on Lord Rama and Ravana's epic battle.'Ramayana' features Ranbir Kapoor as Lord Rama, Sai Pallavi as Goddess Sita, and 'KGF' actor Yash as Ravana. Sunny Deol will portray Lord Hanuman, and Ravi Dubey essays Lakshman in the first glimpse of 'Ramayana' featuring Ranbir and Yash recently gained a lot of appreciation. The epic-drama marks the musical collaboration between Zimmer and AR for IMAX, the first part of 'Ramayana' is slated for release during Diwali 2026, with the second part following in Diwali 2027.- EndsMust Watch
Time of India
16-07-2025
- Entertainment
- Time of India
Hans Zimmer asked not to explain Ramayana to him, says Namit Malhotra: ‘He insisted AR Rahman's name should go first'
Ramayana continues to be one of the most anticipated cinematic spectacles in the making, and producer Namit Malhotra is slowly giving fans a glimpse into its ambitious scale. In a recent podcast with Prakhar Gupta, the DNEG and Prime Focus chairman revealed how The Lion King and Interstellar composer Hans Zimmer reacted when he was first introduced to the story of the Indian epic. 'So beautifully put by someone who doesn't know Ramayana' Namit recalled that when he began explaining Ramayana to Zimmer, the latter stopped him midway. 'He asked me not to explain anything,' said Namit. Curious, he asked the composer why. 'Hans replied, 'It's clearly something beyond us. You and I don't need to explain it.'' Expanding on Zimmer's words, Namit quoted him saying: 'You don't have to explain it (Ramayana) to me. Something that has lived through thousands of years, generations of people, and continues to be relevant after all of that time — you and I don't need to explain it. Something is there, why it is relevant even today. Let's acknowledge it and let's do the best we can because it's clearly something that's beyond us.' For Namit, Zimmer's respectful response was humbling. 'I was like that is so beautifully put by someone who doesn't know anything about Ramayana. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Paras Sector 59 Gurgaon | Paras Floret Low-Rise Flats Paras The Florett Book Now Undo But he is giving reverence and saying just the fact that it exists and continues to be relevant... people feel emotionally about it and passionately about it. That's it. I did not need more.' Sunny Deol to Play 'Lord Hanuman' in 'Ramayana'| Gets '15 Minutes of High-Octane Screen Time' When Zimmer insisted AR Rahman's name should go first The mega-budget film brings together two titans of music, Hans Zimmer and AR Rahman, in a rare collaboration that is already being touted as historic. Namit shared what it's like to witness the duo working together: 'I have sometimes sat there and witnessed the two of them together. I'm like... there is so much mutual respect, so much admiration for each other's work that, as artists, it's actually something to learn from. ' He also recalled a touching moment of cultural exchange between the two maestros. While finalising the name placement in the promotional material, Zimmer said Rahman's name should be listed first (on the left). But Rahman gently responded, 'Sir, you are part of our culture. You are our guest. We have invited you into this. So our culture says you come first, I come second.' Ramayana budget crosses Rs 4000 crore Backed by a reported production cost of USD 500 million (over Rs 4000 crore), Ramayana will be released as a duology. The first part, directed by Nitesh Tiwari, is eyeing a Diwali 2026 release. Ranbir Kapoor will play Lord Rama, while Yash takes on the role of Ravana, with an ensemble cast that remains under wraps but is expected to include top-tier talent from across the industry.
Yahoo
16-07-2025
- Business
- Yahoo
Zimmer bets on autonomous surgery with Monogram purchase
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Zimmer Biomet hopes to round out its surgical robotics portfolio with its planned $177 million purchase of Monogram Technologies, which was announced Monday. The acquisition could offer more customer choice, analysts wrote, but they also questioned whether surgeons will prefer an autonomous robot. Monogram received Food and Drug Administration clearance in March for a semi-autonomous, AI-navigated robot called mBôs, to be used in total knee replacement surgeries. The company plans to launch mBôs with Zimmer's Persona knee implants in early 2027, according to an investor presentation. Monogram is working on a fully autonomous version of the robot, which would be hands-free and activated using foot pedals, that it plans to launch in late 2027 or early 2028. Zimmer already has a robot that can be used for total knee replacements, called Rosa, but that system currently does not work with CT imaging and uses manual cutting. After closing, Zimmer expects to have 'the most comprehensive suite of customer-centric technology solutions, ranging from simplified navigation, such as OrthoGrid, to non-CT based robotics with Rosa, and fully autonomous robots with mBôs,' according to the investor presentation. Analysts said the deal is designed to give surgeons more options, but also raised questions about the acquisition. Mike Matson, an analyst with Needham, said buying Monogram may 'improve and differentiate' Zimmer's robotics, but questioned the level of surgeon interest in a fully automated robotics system, in a research note published Monday. BTIG analyst Ryan Zimmerman wrote in a research note that the price was high for a robotics system that has not sold any units yet, and asked what the deal means for Rosa, given the updates planned for the coming quarters. 'This is about customer choice, defining the fully autonomous category of robotics, and appealing to surgeons who prefer autonomous cutting over manual cutting (which is ROSA today),' Zimmerman wrote, citing a conversation with the orthopedic firm's management. Shagun Singh, an analyst with RBC Capital Markets, wrote that Zimmer plans to grow its business by gaining more share in the robotic market, increasing how many procedures are done using robotics, driving more revenue per procedure, and expanding the market by creating a new category of fully autonomous robots. More acquisitions likely to come Zimmer also used the announcement to outline future plans for its robotics program. The company's Rosa robots are 'rapidly approaching 2,000 installations worldwide' and are a market leader outside of the U.S., Zimmer said in a press release. Zimmer received FDA clearance last year to use Rosa for robot-assisted shoulder replacements, and plans a full launch of the feature in early 2026. The company is working on a posterior hip feature for Rosa for the second half of 2026, and a CT imaging feature for early 2027, according to the investor presentation. Last year, Zimmer bought OrthoGrid Systems, which makes AI guidance systems for total hip replacement surgeries. It also struck a distribution agreement with Think Surgical, which makes a CT-enabled, handheld robot. 'Management explained that these technologies are not competitive, but allow a more complimentary suite,' Singh wrote. In April, Zimmer bought Paragon 28, an orthopedics company focused on foot and ankle procedures, for $1.1 billion. Analysts see Zimmer as poised to continue its streak of acquisitions. Needham's Matson wrote that 'despite the recent acquisition of Paragon 28 and today's announcement, we still think that [Zimmer] may pursue additional acquisitions in higher-growth orthopedic subcategories like data/AI, enabling technologies, sports medicine, and extremities.' Recommended Reading Zimmer to buy robotics firm Monogram for about $177M Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
